Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
MWN-AI** Summary
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has announced a significant research collaboration with University Hospital Essen to enhance prostate cancer management through the PROMISE-PET registry. This initiative aims to define the prognostic value of PSMA-PET imaging using artificial intelligence (AI). The PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET study is a multicenter, observational registry that has been active since 2018, gathering and analyzing data from over 15,000 patients across more than 50 institutions globally. The standardized framework utilized has established PSMA-PET as a novel prognostic biomarker in prostate cancer.
The primary focus of the collaboration is to develop and validate AI-based predictive models for patient survival, utilizing gallium-68 (68Ga)-PSMA-11-PET imaging data alongside Telix's automated machine learning platform. This study aims to compare the effectiveness of AI-enhanced prognostic models against established clinical risk scores, thereby facilitating improved risk stratification for patients both in early and advanced stages of prostate cancer.
As PSMA-PET imaging is increasingly recognized as the standard of care due to its superior accuracy over conventional imaging methods, the collaboration seeks to further investigate the correlation of imaging data with patient outcomes. Experts from both institutions, including Professor Wolfgang Fendler from University Hospital Essen and Telix's Director of AI Research, Simon Wail, emphasize the potential of their combined efforts to provide critical insights that could reshape clinical guidelines and decision-making in prostate cancer treatment.
Telix Pharmaceuticals remains at the forefront of innovation in the biopharmaceutical sector, focusing on developing radiopharmaceuticals aimed at addressing unmet medical needs in oncology.
MWN-AI** Analysis
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) recently announced a strategic collaboration with University Hospital Essen to enhance its PROMISE-PET registry. This initiative aims to validate the prognostic value of PSMA-PET imaging through AI, a significant advancement for prostate cancer management. Given the increasing recognition of PSMA-PET for its accuracy compared to conventional imaging techniques, this collaboration enhances Telix's position in the oncology market and offers investors a compelling narrative.
Investors should consider several factors as they analyze Telix’s future potential. First, the large patient dataset—over 15,000 patients—afforded by PROMISE-PET provides a valuable asset for building robust AI models that can improve patient outcomes. This positions Telix favorably against competitors who lack such extensive data, potentially driving market share as guidelines increasingly recommend standard-of-care practices.
Moreover, the emphasis on AI-driven methodologies signifies a trend within healthcare towards personalized medicine, aligning with Telix’s commitment to addressing unmet needs in oncology. The collaboration may lead to breakthroughs that significantly enhance risk stratification and influence clinical decision-making, fostering stronger relationships with healthcare providers.
Financially, investors should remain cognizant of the company's existing products, such as the approved Illuccix® for PET imaging, which contributes to revenue generation. Continuous innovation through collaborations may boost Telix's market valuation, especially if outcomes from the PROMISE-PET registry yield favorable insights.
While the market presents opportunities, it is essential to acknowledge the inherent risks. Regulatory challenges and competition in the biopharmaceutical sector can impact Telix’s trajectory. Investors should monitor upcoming clinical trial results and regulatory submissions closely.
In summary, Telix’s collaboration with University Hospital Essen represents a significant step towards leveraging AI in prostate cancer management, defining its strategic advantage. Investors may find the stock attractive, particularly as the company bolsters its position in a rapidly evolving healthcare landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI).
PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET is a multi-center, prospective, observational, non-interventional registry study designed to enable research assessing the prognostic value of PSMA-PET and comparing it with established clinical risk scores in early and late stages of disease. The registry has been collecting and analyzing patient data since 2018 and, to date, PET readings from more than 15,000 patients across over 50 institutions globally have been standardized using the PROMISE framework, with PSMA-PET and PROMISE confirmed as a novel prognostic biomarker for prostate cancer using both internal and external validation cohorts3.
The aim of this new collaboration with Telix is to develop and validate AI-based prediction models for survival, leveraging gallium-68 (68Ga)-PSMA-11-PET imaging data, using the automated machine learning (“AutoML”) engine that powers Telix’s AI platform4, and comparing performance with established clinically prognostic nomograms. PSMA-PET imaging represents a significant advance in prostate cancer management and is now considered standard of care, offering greater accuracy than conventional imaging (computed tomography and bone scans) after initial diagnosis and for detecting recurrence5. However, there remains an opportunity to better understand whether PSMA-PET imaging data can be correlated to patient outcomes.
Wolfgang Fendler, MD, Professor, Department of Nuclear Medicine, University Hospital Essen, commented, “We are pleased to welcome Telix – a leading global innovator in radiopharma – to the PROMISE-PET registry to support us in this important research in prostate cancer. Telix’s AI platform has the potential to build on existing results and leverage one of the world’s largest PSMA-PET datasets to support improved risk stratification and inform future guideline recommendations and clinical decision making.”
Simon Wail, Director of AI Research, Telix, added, “Joining the PROMISE-PET registry is an exciting moment for Telix. Working together with leading investigators and having access to global, longitudinal, standardized PSMA-PET data will enable us to build, test and validate clinically relevant prognostic models that we believe will help clinicians in their treatment and management of patients with prostate cancer.”
For further information on the PROMISE-PET registry, visit: https://www.promise-pet.org
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA6.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.)? Ms. Annie Kasparian? Director Investor Relations and Corporate Communications? annie.kasparian@telixpharma.com | ||
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.?To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
_______________________________
1 ClinicalTrials.gov ID: NCT06320223.
2 Imaging of prostate-specific membrane antigen with positron emission tomography.
3 Eiber et al. J Nucl Med. 2018 (PROMISE V1); Seifert et al. European Urology. 2023 (PROMISE V2).
4 Telix ASX disclosure April 27, 2023.
5 EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5; Fendler et al. EJNMMI. 2023.
6 Telix ASX disclosure 21 March 2025.
FAQ**
How does Telix Pharmaceuticals Ltd TLPPF's research collaboration with University Hospital Essen on the PROMISE-PET registry enhance the understanding of PSMA-PET imaging's prognostic value for prostate cancer in Melbourne, Australia?
What role does the AI platform developed by Telix Pharmaceuticals Ltd TLPPF play in refining prognostic models for prostate cancer, particularly in relation to the findings from the PROMISE-PET registry operated in Melbourne and Indianapolis?
In what ways could the data collected from the PROMISE-PET registry by Telix Pharmaceuticals Ltd TLPPF impact future clinical decision-making for prostate cancer treatment in both Melbourne, Australia and Indianapolis, USA?
How might the achievements of Telix Pharmaceuticals Ltd TLPPF in prostate cancer management through PSMA-PET imaging influence global healthcare practices, particularly comparing those in Melbourne and Indianapolis?
**MWN-AI FAQ is based on asking OpenAI questions about Telix Pharmaceuticals Limited (NASDAQ: TLX).
NASDAQ: TLX
TLX Trading
-3.99% G/L:
$7.22 Last:
21,681 Volume:
$7.31 Open:
